From Partnered ASO Therapies To A Wholly-Owned Pipeline With Ionis's Brett Monia, Ph.D.
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Brett Monia, Ph.D., CEO at Ionis Pharmaceuticals, talks about how antisense oligonucleotides (ASO) graduated from a late-1980s lab concept to real RNA-targeting medicines, and why Ionis stuck with a difficult modality despite multiple setbacks. Brett describes the company's shift from a partner-first model to building a wholly-owned pipeline, commercial function, and an expanded manufact...
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from Business Of Biotech
Derisking CNS Drug Development With Tortugas Neuroscience's Jeff Jonas, M.D.
Rare Disease Drug Commercialization With Zevra Therapeutics' Neil McFarlane
Scaling Manufacturing For Personalized Cell Therapies With Cellino's Marinna Madrid, Ph.D.
Building A New Antibody Discovery Platform With Infinimmune's Wyatt McDonnell, Ph.D.
Get summaries like this every morning.
Free AI-powered recaps of Business Of Biotech and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.